AstraZeneca to cut some direct-to-patient US drug prices after Trump demand

AstraZeneca announced it will sell its diabetes drug Farxiga and asthma drug Airsupra directly to cash-paying U.S. patients at discounts of up to 70% off list prices, effective October 1. This move, which bypasses traditional intermediaries like PBMs, is a direct response to U.S. government pressure to lower drug costs and follows similar initiatives from other major pharmaceutical companies. The strategy aims to address a care gap for uninsured and underinsured patients, signaling a broader industry trend toward direct-to-consumer models amidst intense regulatory scrutiny on drug pricing and distribution, complementing the company's recent $50 billion U.S. investment plan.

Analysis

AstraZeneca is launching a direct-to-consumer (D2C) sales platform in the U.S., a strategic pivot in response to significant political pressure from the Trump administration to lower drug prices. Effective October 1, the company will sell its blockbuster diabetes drug, Farxiga, for $182 and its asthma treatment, Airsupra, for $249, representing discounts of up to 70% and 50% from list prices, respectively. This initiative, which bypasses traditional intermediaries like pharmacies and pharmacy benefit managers (PBMs), targets uninsured and underinsured cash-paying patients. The move is financially significant as Farxiga generated $7.7 billion in 2024, accounting for approximately 14% of AstraZeneca's total revenue. While the company states the program aims to close a "genuine care gap," the ultimate benefit to patients and the financial impact on AstraZeneca remain uncertain, as the size of the addressable cash-pay market is not specified. This strategy aligns AstraZeneca with industry peers such as Eli Lilly, Novo Nordisk, and Bristol Myers Squibb, who have launched similar D2C programs, signaling a broader industry shift toward this model amidst heightened regulatory scrutiny. The initiative complements AstraZeneca's larger strategic efforts to navigate U.S. trade policy, including its recently announced $50 billion domestic investment plan to bolster its U.S. manufacturing presence.

Key Decisions for Investors

• Investors should view this D2C initiative as a proactive, albeit defensive, move to mitigate political and pricing risks in the crucial U.S. market, though its near-term revenue impact is likely limited given the undefined size of the cash-pay segment.
• Monitor for potential channel conflict and strained relationships with PBMs, as bypassing these intermediaries for key drugs like Farxiga could risk unfavorable formulary placement for AstraZeneca's broader portfolio in the future.
• Consider this D2C channel in conjunction with the company's $50 billion U.S. investment plan as a comprehensive strategy to de-risk its U.S. operations from both pricing pressure and potential tariff impacts, positioning it to maintain market access and supply chain stability.
• Benchmark the performance of AstraZeneca Direct against the D2C platforms of peers like Eli Lilly (Zepbound) and Novo Nordisk (Wegovy) to assess its competitive effectiveness and the overall viability of this emerging sales model in the pharmaceutical sector.